
    
      A phase IIa, randomised, double-blind, placebo-controlled study using outpatient setting to
      assess the prophylactic effect of repeated intranasal dosing of PrEP-001 in healthy subjects,
      subsequently challenged with HRV-16, on the changes in clinical symptoms when compared to
      placebo at two different dosing regimens
    
  